BRIEF-Merck & Co says FDA also approves a labeling update for Keytruda for treatment of patients with metastatic NSCLC

* FDA approves Merck's KEYTRUDA (pembrolizumab) in metastatic NSCLC for first-line treatment of patients whose tumors have high PD-l1 expression (tumor proportion score of 50 percent or more) with no EGFR or ALK genomic tumor aberrati